Alembic receives USFDA’s final approval for Fluphenazine Hydrochloride Tablets

Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr

Reported profit after tax declined 19% year-on-year to Rs 76 crores

USFDA successfully inspects Carbogen Amcis’s manufacturing sites in Neuland and Aarau

The inspections concluded with no Form 483 observations or significant critical findings

Caplin Steriles gets USFDA approval for Ephedrine Sulfate injection USP

Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension

Bayer announces positive topline results for Nubeqa from Phase III trial in men with mHSPC

Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT

Industry hails Union Budget 2024-25

The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable

Poly Medicure posts Q1 FY25 consolidated PAT at Rs. 74.03 Cr

Poly Medicure has reported total income of Rs. 401.69 crores during the period ended June 30, 2024

Solara Active Pharma Sciences reports Q1 FY25 consolidated loss at Rs. 13.46 Cr

Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024

Zydus receives approval from COFEPRIS of Mexico to market ‘Bhava’ to treat various cancers

RPG Life Sciences posts Q1 FY25 PAT higher at Rs. 26.76 Cr

RPG Life Sciences has reported total income of Rs. 167.79 crores during the period ended June 30, 2024